Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228221 · ClinicalTrials.gov registry record · Phase 4
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
A Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma, sponsored by Jonathon Myers.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07228221: Recruiting Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma, sponsored by Jonathon Myers.
NCT07228221 is a Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma that is actively recruiting participants, run by Jonathon Myers. The registered enrollment target is 20 participants, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228221, a Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma, is actively recruiting participants, sponsored by Jonathon Myers.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.
Primary Outcome
a logistic regression model will be used for the imputation of missing values, using the 12-month performance outcome as dependent variable, and sex, race, age, baseline IOP, number of IOP-lowering medications used at baseline, last IOP and number of medications at the 6-month visit or later as explanatory variables.
Conditions Studied
Interventions
- DEVICE iStent infinite trabecular micro-bypass system model iS3
- DRUG iDose TR (Travoprost intracameral Implant) 75mcg
Study Locations (1)
Pennsylvania
- Wills Eye Hosital Glaucoma Dept. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 4 |
What NCT07228221 shows while recruiting
NCT07228221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which iStent infinite trabecular micro-bypass system model iS3 is the first listed.
NCT07228221 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07228221 about?
NCT07228221 is a clinical study titled "Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma". The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open a...
What is the current status of trial NCT07228221?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-01-05. Estimated completion is 2031-12-31.
What conditions does trial NCT07228221 study?
This clinical trial studies the following conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma.
What interventions are being tested in trial NCT07228221?
The interventions under investigation include: iStent infinite trabecular micro-bypass system model iS3 (DEVICE), iDose TR (Travoprost intracameral Implant) 75mcg (DRUG).
Who is sponsoring clinical trial NCT07228221?
This trial is sponsored by Jonathon Myers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228221 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228221's enrollment target sits among peer trials
20 26th of 28 higher than 2 of 28 other Open Angle Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI